Menu
Search
|

Menu

Close
X

Impax Laboratories Inc IPXL.OQ (NASDAQ Stock Exchange Global Select Market)

19.60 USD
+0.20 (+1.03%)
As of Feb 17
chart
Previous Close 19.40
Open 19.35
Volume 176,718
3m Avg Volume 274,671
Today’s High 20.20
Today’s Low 19.23
52 Week High 25.70
52 Week Low 7.80
Shares Outstanding (mil) 74.31
Market Capitalization (mil) 1,620.01
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.64 Mean rating from 14 analysts

KEY STATS

Revenue (mm, USD)
FY17
386
FY16
824
FY15
860
EPS (USD)
FY17
-1.659
FY16
-6.610
FY15
0.535
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
1.99
5.77
Price to Book (MRQ)
vs sector
3.08
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
149.26
16.52
LT Debt to Equity (MRQ)
vs sector
145.87
12.22
Return on Investment (TTM)
vs sector
-39.49
14.43
Return on Equity (TTM)
vs sector
-72.27
16.13

EXECUTIVE LEADERSHIP

Robert Burr
Independent Chairman of the Board, Since
Salary: --
Bonus: --
Paul Bisaro
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Bryan Reasons
Chief Financial Officer, Senior Vice President - Finance, Since 2012
Salary: $496,620.00
Bonus: --
Douglas Boothe
President - Generics Division, Since 2016
Salary: $207,692.00
Bonus: $250,000.00
Michael Nestor
President - Impax Specialty Pharmaceutical Division, Since 2008
Salary: $548,908.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

30831 Huntwood Ave
HAYWARD   CA   94544-7003

Phone: +1510.2406000

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

SPONSORED STORIES